You're using an outdated browser. Please upgrade to a modern browser for the best experience.
N-Acetylcysteine and Atherosclerosis: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Sirius Huang and Version 1 by Greg Flaker.

Atherosclerosis remains a leading cause of cardiovascular diseases. Although the mechanism for atherosclerosis is complex and has not been fully understood, inflammation and oxidative stress play a critical role in the development and progression of atherosclerosis. N-acetylcysteine (NAC) has been used as a mucolytic agent and an antidote for acetaminophen overdose with a well-established safety profile. NAC has antioxidant and anti-inflammatory effects through multiple mechanisms, including an increase in the intracellular glutathione level and an attenuation of the nuclear factor kappa-B mediated production of inflammatory cytokines like tumor necrosis factor-alpha and interleukins. Numerous animal studies have demonstrated that NAC significantly decreases the development and progression of atherosclerosis.

  • atherosclerosis
  • N-acetylcysteine
  • inflammation
  • oxidative stress
  • antioxidant

1. Introduction

Atherosclerosis remains a leading cause of cardiovascular diseases (CVDs) globally and is considered a chronic inflammatory disease, with increased levels of reactive oxygen species (ROS) and oxidative stress [1,2][1][2]. Antioxidants, which inhibit oxidation, would be expected to have a favorable impact on patients with atherosclerosis. However, the Heart Outcomes Prevention Evaluation (HOPE) Study [3], a double-blind and randomized trial with patients at high risk for cardiovascular events, showed that treatment with antioxidant vitamin E had no beneficial effect over a mean follow-up of 4.5 years. Although there were no significant adverse effects of vitamin E, the primary outcome (a composite of myocardial infarction, stroke, and death from cardiovascular causes) and the secondary outcomes (including unstable angina, congestive heart failure, revascularization or amputation, death from any cause, complications of diabetes, and cancer) were the same in patients either on vitamin E or placebo [3]. Studies with antioxidant β-carotene treatment also failed to achieve significant clinical benefits in patients with CVDs, including atherosclerosis [4].
N-Acetylcysteine (NAC) is approved by the Food and Drug Administration (FDA) for the treatment of acetaminophen overdose. Although not approved for use as a dietary supplement, NAC has been widely used for acute respiratory distress syndrome, bronchitis, chemotherapy-induced toxicity, human immunodeficiency virus/acquired immune deficiency syndrome, radio-contrast-induced nephropathy, heavy metal toxicity, psychiatric disorders, and as an over-the-counter nutritional supplement [5,6][5][6]. In the cardiovascular area, NAC has been used off label for doxorubicin-induced cardiotoxicity, stable angina pectoris, and cardiac ischemia-reperfusion injury [6,7][6][7].
The primary mechanisms for the actions of NAC are considered to relate to its antioxidative effects via increasing intracellular glutathione (GSH) levels (crucial for cellular redox balance) and its anti-inflammatory effect through suppressing nuclear factor kappa B (NF-κB)-mediated expression of a variety of inflammatory mediators, including tumor necrosis factor-alpha (TNF-α) and interleukins (IL-6 and IL-1β) [5].

2. Overview of NAC and Cardiovascular Diseases

As shown in Table 1, the intravenous administration of NAC significantly increases arterial vascular reactivity during reactive hyperemia in patients with chronic kidney disease following hemodialysis [8], reduces vasospasm in patients suffering from subarachnoid hemorrhage [9], and prevents ischemia-reperfusion syndrome following aortic clamping in patients during abdominal aortic aneurysmectomy [10]. NAC has been shown to decrease the frequency and severity of Raynaud’s phenomenon (RP) attacks and digital ulcers (DU) in patients with systemic sclerosis (SSc), with a significant reduction in plasma adrenomedullin concentrations [11,12,13][11][12][13]. Another study also demonstrated that NAC protected patients with RP secondary to SSc against DU, although NAC has no significant vasodilator effect on the microcirculation in hands [14].
Table 1.
Clinical studies with NAC in patients with peripheral vascular disease (PVD).
Patient Information Intervention Outcome Ref.
Pts (6 M and 16 F, YOA: 18–75) with RP secondary to SSc NAC i.v. starting with a 2 h loading dose of 150 mg/kg, then 15 mg/kg/h for 5 days Both frequency and severity of RP attacks, active ulcers, and old challenge test mean recovery time decreased [11]
Pts (7 M and 43 F; YOA: 35–67)

with RP secondary to SSc		 NAC i.v. 15 mg/kg/h for 5 h in every 14 days for about 3 years Reduction of DU, RP attacks, and RP DU ulcer visual analog scale [12]
Pts (4 M and 22 F, YOA: 25–68) with RP secondary to SSc NAC i.v. 15 mg/kg/h for 5 h, every 2 weeks for 2 years Increased global hands perfusion and decreased plasma adrenomedullin concentrations, frequency and severity of RP attacks [13]
Pts (42 M, YOA: 32–58) with RP secondary to SSc NAC oral 600 mg tid for 4 weeks Decreased DU but no vasodilator effect on hands’ microcirculation [14]
Pts (20 M and 4 F, YOA: 56–78) with stage 5 CKD during hemolysis NAC i.v. 5 g in 5% glucose in a final volume of 50 mL during one hemodialysis session Improved arterial vascular reactivity during reactive hyperemia with decreased reflective index [8]
Pts (total 36, YOA: 56–76, without or with only minor signs of preoperative ischemia of the lower body) undergoing elective infrarenal AAA NAC i.v. 150 mg/kg b.m. 30 min before infrarenal aortic clamping Prevented elevation of plasma lipid peroxide, thromboxane, and prostacyclin levels after declamping with increased plasma GSH concentration for over 12 h [10]
NAC: N-acetylcysteine; Pts: patients; M: male; F: female; YOA: years of age; RP: Raynaud’s phenomenon; SSc: systemic sclerosis; mg: milligram; kg: kilogram; h: hour; Ref: references; i.v.: intravenous infusion; DU: digital ulcer; tid: three times a day; AAA: abdominal aortic aneurysm; b.m.: body mass; b.w.: body weight; CKD: chronic kidney disease; GSH: glutathione.
NAC has been reported to protect against coronary artery diseases (CAD), myocardial infarction (AMI), myocardial injuries, and cardiomyopathy [15,16,17,18,19,20][15][16][17][18][19][20]. In patients with cardiac surgery, NAC decreases diabetes-associated cardiovascular, cardiopulmonary bypass, and cardiac surgery complications, including early reperfusion injury, pump-induced inflammatory response, and myocardial stress [21,22,23][21][22][23]. However, a systematic review has shown that NAC has no significant efficacy in improving major adverse outcomes, including mortality, acute renal failure, HF, length of stay and/or outcomes of care in intensive care unit, arrhythmia, and AMI, in patients following cardiac surgery [24]. Multiple clinical studies have demonstrated that NAC treatment effectively reduces the risk of atrial fibrillation (AF), a common arrhythmia post cardiac surgery [25,26[25][26][27][28][29],27,28,29], although one study reveals that a high dose of oral NAC treatment had no benefit on postoperative AF [30]. In addition, NAC has been reported to improve HF [31] however, no beneficial effect was observed in patients with doxorubicin-induced cardiomyopathy [32,33][32][33]. Animal studies have shown that NAC improves peripheral vascular diseases (PVD), with reduced muscular fatigue [40][34], restoration of redox balance and calcium retention capacity, as well as the suppression of reactive oxygen species (ROS) production in mice with hind limb ischemia [41][35]. NAC prevented excessive intracellular and extracellular ROS formation in mice with limb ischemia and enhanced the recovery of ischemic limb blood flow and function, in association with a selective increase in circulating endothelial progenitor cell (EPC) numbers (a group of cells critical for endothelial and vascular function) [42,43][36][37]. NAC treatment also attenuated C-reactive protein-induced ROS production in EPCs and apoptosis in vitro [44][38]. Animal studies also demonstrated that treating low-density lipoproteins (LDL) receptor deficient (LDLR KO) mice on a high-fat diet (HFD) with NAC in drinking water for 4 months significantly decreased ROS production and partially reversed the effects of hyperlipidemia on EPC populations [45][39]. Another animal study has revealed that NAC treatment effectively attenuated atherosclerosis progression following particulate matter (PM) exposure in LDLR KO mice with HFD, prevented excessive ROS generation, and reduced the levels of circulating oxidized LDL (ox-LDL) and inflammatory cytokines [46][40]. Preclinical animal studies have also shown that NAC normalized serum TNF-α level that was resistant to etanercept or infliximab, and improved HF in rats with cardiac injury [47,48,49][41][42][43]. A systematic review has demonstrated that NAC significantly decreased diabetes-associated cardiovascular complications including ischemia and non-ischemia cardiac damage through inhibition of oxidative stress in various animal models [23].

3. NAC and ROS

Excessive ROS plays a critical role in the development and progression of atherosclerosis. Many atherosclerogenic risk factors, including hypertension, diabetes, smoking, and dyslipidemia, increase ROS production, trigger inflammatory response, alter vascular function, and promote the growth of vascular smooth muscle [50,51,52][44][45][46]. NAC has been reported to prevent atherosclerosis formation in various animal models. Treatment of hypercholesterolemic rabbits with NAC significantly decreased the gelatinase expression, gelatinolytic activity, and matrix metalloproteinases (MMP)-9 expression in foam cells [53][47]. Similarly, it has been reported that treating atherosclerotic rabbits with NAC for 8 weeks significantly attenuated atherosclerotic formation, in association with a reduction in blood ox-LDL, MMP-9, MMP-2, and expression of MMP mRNA [54][48]. Using human THP-1 cells treated with phorbol 12-myristate 13-acetate for 48 h, followed by ox-LDL incubation for 4 days to induce foam cell formation, NAC treatment significantly reduced ROS production and ox-LDL uptake, leading to an inhibition of foam cell formation via a down-regulation of CD36 expression [55][49]. Another study reports that the treatment of apolipoprotein E knockout (ApoE KO) mice with NAC orally for 8 weeks significantly attenuated the progression of atherosclerosis, with decreased plaque collagen content and nitrotyrosine expression, probably via a reduction in oxidative stress [56][50]. In addition, aortic fatty streak plaque was effectively prevented in ApoE KO mice when treated with NAC via intraperitoneal injection for 8 weeks, with a reduction in aortic wall superoxide production [57][51]. A study shows that NAC treatment in drinking water for 12 weeks suppressed atherosclerotic development in ApoE KO mice with streptozotocin-induced type-1 diabetes, in association with improved GSH-dependent methylglyoxal elimination, decreased oxidative stress, and the restoration of phosphorylated Akt (p-Akt)/phosphorylated endothelial nitric-oxide synthase (p-eNOS) pathways in aortas [58][52]. Native LDL per se is not atherogenic, and ox-LDL is one of the key components in hyperlipidemic states and a potent source of ROS [45,64,65][39][53][54]. NAC could inhibit the in vitro oxidation of LDL and prevent the depletion of antioxidant vitamins [66][55]. One study has shown that NAC treatment also effectively attenuated the in vivo biotransformation of human native LDL to ox-LDL in a mouse model [60][56]. In a small study with 10 patients with CAD and hyperlipidemia, NAC treatment for 7 days significantly decreased the serum ox-LDL level, while there was no significant change in the serum ox-LDL level in patients with placebo [60][56]. These data suggest that NAC decreases ROS levels through multiple mechanisms, including an inhibition of the in vivo biotransformation of native LDL to ox-LDL.

4. NAC, Inflammation, and Macrophages

Inflammation is closely related to the development and progression of CVDs, especially atherosclerosis. Myeloid cells-mediated innate immune responses significantly contribute to chronic vascular inflammation [67][57]. It has been reported that treatment of human umbilical vein endothelial cells (HUVEC) with NAC effectively blocks the interleukin (IL)-4-induced expression of vascular cell adhesion molecule-1, which stimulates the adhesion of lymphocytes and monocytes to the surface of the vascular endothelium during the early phase of atherosclerosis development [68,69][58][59]. IL-6 is known to increase inflammation and the development of vascular diseases, including atherosclerosis. NAC treatment inhibits the production of IL-6 in acetoacetate-treated human U937 monocytes [70][60]. Lysophosphatidylcholine is produced from the hydrolysis of phosphatidylcholine by secretory phospholipase A2 (sPLA2) and has proinflammatory and proatherogenic effects on the vasculature [71][61]. NAC treatment significantly reduced TNF-α-induced expressions of group V sPLA2 (sPLA2-V) mRNA and protein in HUVEC [72][62]. Intraperitoneal injection NAC significantly attenuated balloon-induced neointimal formation in the carotid artery in rats via the inhibition of NF-κB activity in the medial smooth muscle cells [73][63]. Treatment of hyperlipidemic rabbits with a combination of the anti-inflammatory drug colchicine with fenofibrate or NAC for 7 weeks significantly reduced aortic atherosclerotic plaque. However, the atherosclerotic burden was significantly lower in the hyperlipidemic rabbits treated with a combination of colchicine with NAC compared with that of colchicine plus fenofibrate. Serum IL-6 levels were also significantly decreased in animals treated with colchicine plus NAC [63][64]. Macrophages are one of the important sources for inflammatory cytokines [74][65] and play a critical role in the pathogenesis of atherosclerosis [75][66]. An increase in macrophage polarization to proinflammatory macrophages (M1), or a decrease to anti-inflammatory macrophages (M2), increases the level of inflammation and promotes atherosclerotic progression [76][67]. Thus, the M1/M2 ratio is an important determinant for the direction of inflammatory response [77][68]. Macrophages are also important for the stability of atherosclerotic plaques [78][69]. The data from a study using aging LDLR−/− mice showed that inflammatory markers (CRP, MCP-1, and IL-6) were significantly increased, while the anti-inflammatory cytokine IL-10 was significantly decreased in aging LDLR−/− mice, in association with a significantly increased aortic ROS level and an increased M1/M2 ratio, largely due to decreased M2 population in the aorta. Further studies using bone marrow transplants with GFP-labeled bone marrow cells showed that the increased M1/M2 ratio in the aorta of aging LDLR−/− mice was predominantly due to decreased M2 polarization, without a significant change in M1 polarization. NAC treatment effectively prevented changes in the expressions of pro-inflammatory and anti-inflammatory cytokines, the ROS level, and macrophage polarization in the aorta of aging LDLR−/− mice. Interestingly, NAC treatment has no effect on the migration of monocytes from circulation into the aorta in aging LDLR−/− mice or on M1 population in the aorta [59][70].

5. NAC and Atherosclerosis and CAD

Atherosclerosis and related CAD are a leading cause of mortality and morbidity in the world [79][71]. A multicenter clinical study, NAC in acute MI (NACIAM), with 112 patients, has shown that a combination of intravenous NAC treatment with a low dose of nitroglycerin (NTG) significantly shrinks the infarction size in patients with acute ST elevation MI undergoing primary percutaneous coronary intervention (PCI) [34][72]. Two more small studies (28 and 30 patients each) have reported that the combination of NAC with NTG and streptokinase reduced the levels of oxidative stress and plasma malondialdehyde (MDA), and improved left-ventricular function in patients with acute MI [35,36][73][74]. Similar results have been reported when NAC supplemented cold-blood cardioplegia [37][75] or when NAC was added to crystalloid cardioplegia in patients with CAD following a coronary artery bypass graft (CABG) [38][76]. NAC was also shown to potentiate the effects of NTG on the treatment of patients with unstable angina pectoris and other CAD patients [39,80][77][78]. A review of data from clinical studies has shown that NAC has cardioprotective effects in patients who had ischemic heart disease and underwent CABG and PCI [81][79]. However, a recent systematic review of 29 clinical trials with 2486 participants and a meta-analysis with 578 patients have demonstrated that NAC treatment does not significantly reduce major adverse events in patients undergoing cardiac surgery, including AMI and mortality [24,82][24][80]. Animal studies have shown that the intraperitoneal injection of NAC prevented nonthyroidal illness syndrome-related thyroid hormone derangement and preserved cardiac function in male rats with acute ischemic myocardial injury via the restoration of the redox balance [84][81]. Intravenous injection of NAC decreased oxidative stress, infarct area, and apoptosis in a rat cardiac ischemia-reperfusion injury model [85][82]. However, intracoronary administration of NAC in a pig model that simulated a catheter-based reperfusion model for the therapy of acute ST-elevated MI (STEMI) showed no significant effect on reducing the infarction size [86][83]. A recent study, using an aging LDLR−/− mouse model with a regular diet, has demonstrated that NAC treatment significantly decreased aortic ROS levels and inflammatory cytokines in the serum and aortas of aging LDLR−/− mice. The same study has also shown that early and adequate NAC treatment could effectively attenuate atherosclerosis progression in aging LDLR−/− mice without extreme hyperlipidemia [59][70].

6. NAC and Lipid Metabolism

The disruption of the lipoprotein metabolism plays an important role in the development and progression of atherosclerosis [87][84]. Pretreatment with NAC significantly inhibited the differentiation of murine 3T3-L1 preadipocytes into adipocytes and decreased intracellular fat accumulation and the expressions of obesity-related proteins, including monoamine oxidase A, heat-shock protein 70, aminoacylase-1, and transketolase [88][85]. Similarly, NAC attenuates lipid accumulation and mitogen-activated protein kinases phosphorylation in murine embryonic fibroblasts during adipogenic differentiation [89][86]. Lipoprotein (Lp)(a) binds to apoprotein (a) and is considered an independent risk factor for premature atherosclerosis [90][87]. It has been shown that treating the serum from patients with a high concentration of Lp(a) with a high concentration of NAC (8 mg /mL or above) in vitro leads to dissociation of Lp(a) from apoprotein [91][88]. A small and yet significant reduction in Lp(a) concentration was observed in 12 subjects with a high serum Lp(a) level (87 mg/dL) following 6 weeks of NAC treatment [91][88]. However, another small clinical study of seven subjects with a median Lp(a) concentration of 14.3 mg/dL has demonstrated that NAC treatment for 6 weeks had no significant effect on plasma Lp(a) levels [91][88]. Similarly, no significant effect of NAC treatment on serum Lp(a) levels were found in 11 subjects with serum Lp(a) levels over 0.3 g/L [92][89]. An animal study has shown that treating LDLR KO mice on a HFD with NAC for 2 months or 4 months has no significant effect on the blood lipid profile, including triglycerides (TG), LDL, high-density lipoprotein (HDL), total cholesterol (TC), and non-HDL cholesterol [60][56]. Similarly, no significant effect of NAC treatment (250 mg/day, twice a day for 1 week) on the lipid profile was observed in human subjects with CAD and hyperlipidemia [60][56].

7. NAC and Homocysteine

An increased level of blood homocysteine is arguably considered a risk factor for atherosclerosis through increased oxidative stress, endothelial dysfunction, and thrombosis formation [93][90]. It has been reported that treating human subjects with NAC significantly reduced blood homocysteine levels by 45% over the placebo control [92][89]. The NAC treatment of patients with chronic renal failure led to a 16% reduction in plasma homocysteine levels [94][91]. Intravenous administration of NAC significantly decreased the level of plasma homocysteine in healthy subjects [95][92]. Data from controlled trials in middle-aged male subjects with unmedicated hyperlipidemia, with or without smoking, has shown that oral NAC treatment significantly reduced the level of total plasma homocysteine, regardless of lipid or smoking status [96][93]. However, Miner and colleagues have reported that treating cardiac transplant recipients with NAC had no significant impact on plasma homocysteine levels or brachial endothelial function [97][94].

8. Effects of NAC on Endothelial Cells

Endothelial dysfunction has been considered the first step of atherosclerosis development [98][95]. It was reported that treating endothelial cells from porcine pulmonary arteries with NAC significantly increased intracellular glutathione levels and partially prevented TNF-α-induced endothelial dysfunctions [99][96]. NAC also attenuated aortic endothelial damage in ApoE KO mice with streptozotocin-induced diabetes and HFD in association with increased levels of pAkt and -p-eNOS in aorta, as well as NO in serum [58][52]. Treatment of human aortic endothelial cells (HAEC) with NAC significantly attenuated TNF-α-induced ROS production and the DNA-binding activities of activator protein-1 and NF-κB, as well as p65 Ser276 phosphorylation [100][97]. Long-term treatment of endothelial cells (EC) from arterial segments of patients with severe CAD with NAC delayed senescence of diseased EC via the catalytic subunit of telomerase activation and transient telomere stabilization [101][98]. Intra-arterial infusion of NAC in healthy human subjects at a rate to achieve a blood concentration of 1 mM potentiated the effects of NTG on vasodilation and enhanced the biotransformation to an endothelium-derived relaxing factor equivalent nitrosothiol [102][99]. Intracoronary infusion of NAC in patients with or without coronary atherosclerosis significantly potentiated acetylcholine-induced coronary and femoral vasodilation and SNP-induced coronary vasodilation [103][100].

9. Mechanisms for the Actions of NAC on Atherosclerosis

The mechanisms for the effects of NAC on ROS generation, inflammation and atherosclerosis are very complex and have not been fully defined. Traditionally, NAC is considered to function as an antioxidant through a reduction in disulfide bonds or the scavenging of ROS or replenishing intracellular GSH stores [104][101]. However, in many settings and situations, the mechanisms of actions of NAC have remained unclear. Accumulating data has supported the concept that NAC is more like an anti-inflammatory agent with immunomodulatory properties, through its ability to attenuate the activation of oxidant-sensitive pathways, including the NF-κB and p38 mitogen-activated protein kinase (MAPK) signaling pathways, and subsequent reductions in pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 [5,105,106][5][102][103]. Due to the complex nature of atherosclerosis pathogenesis, the mechanisms for the effects of NAC on atherosclerosis are also complex, including (but not limited to) (1) modifications of lipid metabolism, (2) inhibition of the expressions of gelatinase, MMP-2, and MMP-9, (3) blocking the in vivo biotransformation of native LDL to ox-LDL, and directly suppressing ROS production from ox-LDL, (4) increasing intracellular glutathione levels, and thus protecting endothelial function, (5) attenuation of NF-κB and p38-MAPK signaling, thus decreasing inflammatory cytokine production, (6) the preservation of circulating endothelial cell progenitor cells, (7) reduction of homocysteine levels, (8) attenuation of endothelial senescence and damage, while enhancing endothelial function through multiple mechanisms, including activation of Akt signaling and eNOS, and (9) the preservation of M2 polarization in the hyperlipidemic condition, thus reducing inflammation and oxidative stress, as shown in Figure 1.
Antioxidants 12 02073 g001
Figure 1. Potential mechanisms for the effect of N-acetylcysteine (NAC) on atherosclerosis. EPCs: endothelial progenitor cells; AKT: serine-threonine protein kinase; eNOS: endothelial nitric-oxide synthase; GSH: glutathione; IL: interleukin; LDL: low-density lipoprotein cholesterol; Lp(a): lipoprotein-a; apo(a): apoprotein-a; Ox-LDL: oxidized LDL; NF-κB: nuclear factor kappa-light-chain-enhancer of activated B cells; p38-MAPK: p38 mitogen-activated protein kinase; ROS: reactive oxygen species; TNF-α: tumor necrosis factor-alpha; M1: proinflammatory macrophages; M2: anti-inflammatory macrophages; MMP: matrix metalloproteinases; red arrows: increase; green arrows: decrease.

References

  1. Engelen, S.E.; Robinson, A.J.B.; Zurke, Y.X.; Monaco, C. Therapeutic strategies targeting inflammation and immunity in atherosclerosis: How to proceed? Nat. Rev. Cardiol. 2022, 19, 522–542.
  2. El Hadri, K.; Smith, R.; Duplus, E.; El Amri, C. Inflammation, Oxidative Stress, Senescence in Atherosclerosis: Thioredoxine-1 as an Emerging Therapeutic Target. Int. J. Mol. Sci. 2021, 23, 77.
  3. Heart Outcomes Prevention Evaluation Study Investigators; Yusuf, S.; Dagenais, G.; Pogue, J.; Bosch, J.; Sleight, P. Vitamin E supplementation and cardiovascular events in high-risk patients. N. Engl. J. Med. 2000, 342, 154–160.
  4. Bjelakovic, G.; Nikolova, D.; Gluud, L.L.; Simonetti, R.G.; Gluud, C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst. Rev. 2008, CD007176.
  5. Tenorio, M.; Graciliano, N.G.; Moura, F.A.; Oliveira, A.C.M.; Goulart, M.O.F. N-Acetylcysteine (NAC): Impacts on Human Health. Antioxidants 2021, 10, 967.
  6. Samuni, Y.; Goldstein, S.; Dean, O.M.; Berk, M. The chemistry and biological activities of N-acetylcysteine. Biochim. Biophys. Acta 2013, 1830, 4117–4129.
  7. Sochman, J. N-acetylcysteine in acute cardiology: 10 years later: What do we know and what would we like to know?! J. Am. Coll. Cardiol. 2002, 39, 1422–1428.
  8. Wittstock, A.; Burkert, M.; Zidek, W.; Tepel, M.; Scholze, A. N-acetylcysteine improves arterial vascular reactivity in patients with chronic kidney disease. Nephron Clin. Pract. 2009, 112, c184–c189.
  9. Pereira Filho Nde, A.; Pereira Filho Ade, A.; Soares, F.P.; Coutinho, L.M. Effect of N-acetylcysteine on vasospasm in subarachnoid hemorrhage. Arq. Neuro-Psiquiatr. 2010, 68, 918–922.
  10. Kretzschmar, M.; Klein, U.; Palutke, M.; Schirrmeister, W. Reduction of ischemia-reperfusion syndrome after abdominal aortic aneurysmectomy by N-acetylcysteine but not mannitol. Acta Anaesthesiol. Scand. 1996, 40, 657–664.
  11. Sambo, P.; Amico, D.; Giacomelli, R.; Matucci-Cerinic, M.; Salsano, F.; Valentini, G.; Gabrielli, A. Intravenous N-acetylcysteine for treatment of Raynaud’s phenomenon secondary to systemic sclerosis: A pilot study. J. Rheumatol. 2001, 28, 2257–2262.
  12. Rosato, E.; Borghese, F.; Pisarri, S.; Salsano, F. The treatment with N-acetylcysteine of Raynaud’s phenomenon and ischemic ulcers therapy in sclerodermic patients: A prospective observational study of 50 patients. Clin. Rheumatol. 2009, 28, 1379–1384.
  13. Salsano, F.; Letizia, C.; Proietti, M.; Rossi, C.; Proietti, A.R.; Rosato, E.; Pisarri, S. Significant changes of peripheral perfusion and plasma adrenomedullin levels in N-acetylcysteine long term treatment of patients with sclerodermic Raynauds phenomenon. Int. J. Immunopathol. Pharmacol. 2005, 18, 761–770.
  14. Correa, M.J.; Mariz, H.A.; Andrade, L.E.; Kayser, C. Oral N-acetylcysteine in the treatment of Raynaud’s phenomenon secondary to systemic sclerosis: A randomized, double-blind, placebo-controlled clinical trial. Rev. Bras. Reumatol. 2014, 54, 452–458.
  15. Raghu, G.; Berk, M.; Campochiaro, P.A.; Jaeschke, H.; Marenzi, G.; Richeldi, L.; Wen, F.Q.; Nicoletti, F.; Calverley, P.M.A. The Multifaceted Therapeutic Role of N-Acetylcysteine (NAC) in Disorders Characterized by Oxidative Stress. Curr. Neuropharmacol. 2021, 19, 1202–1224.
  16. Tepel, M.; van der Giet, M.; Statz, M.; Jankowski, J.; Zidek, W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: A randomized, controlled trial. Circulation 2003, 107, 992–995.
  17. Liu, C.; Lu, X.Z.; Shen, M.Z.; Xing, C.Y.; Ma, J.; Duan, Y.Y.; Yuan, L.J. N-Acetyl Cysteine improves the diabetic cardiac function: Possible role of fibrosis inhibition. BMC Cardiovasc. Disord. 2015, 15, 84.
  18. Phaelante, A.; Rohde, L.E.; Lopes, A.; Olsen, V.; Tobar, S.A.; Cohen, C.; Martinelli, N.; Biolo, A.; Dal-Pizzol, F.; Clausell, N.; et al. N-acetylcysteine Plus Deferoxamine Improves Cardiac Function in Wistar Rats After Non-reperfused Acute Myocardial Infarction. J. Cardiovasc. Transl. Res. 2015, 8, 328–337.
  19. Costa, C.R.M.; Seara, F.A.C.; Peixoto, M.S.; Ramos, I.P.; Barbosa, R.A.Q.; Carvalho, A.B.; Fortunato, R.S.; Silveira, A.L.B.; Olivares, E.L. Progression of heart failure is attenuated by antioxidant therapy with N-acetylcysteine in myocardial infarcted female rats. Mol. Biol. Rep. 2020, 47, 8645–8656.
  20. Shafiei, E.; Bahtoei, M.; Raj, P.; Ostovar, A.; Iranpour, D.; Akbarzadeh, S.; Shahryari, H.; Anvaripour, A.; Tahmasebi, R.; Netticadan, T.; et al. Effects of N-acetyl cysteine and melatonin on early reperfusion injury in patients undergoing coronary artery bypass grafting: A randomized, open-labeled, placebo-controlled trial. Medicine 2018, 97, e11383.
  21. Sucu, N.; Cinel, I.; Unlu, A.; Aytacoglu, B.; Tamer, L.; Kocak, Z.; Karaca, K.; Gul, A.; Dikmengil, M.; Atik, U.; et al. N-acetylcysteine for preventing pump-induced oxidoinflammatory response during cardiopulmonary bypass. Surg. Today 2004, 34, 237–242.
  22. Tossios, P.; Bloch, W.; Huebner, A.; Raji, M.R.; Dodos, F.; Klass, O.; Suedkamp, M.; Kasper, S.M.; Hellmich, M.; Mehlhorn, U. N-acetylcysteine prevents reactive oxygen species-mediated myocardial stress in patients undergoing cardiac surgery: Results of a randomized, double-blind, placebo-controlled clinical trial. J. Thorac. Cardiovasc. Surg. 2003, 126, 1513–1520.
  23. Dludla, P.V.; Dias, S.C.; Obonye, N.; Johnson, R.; Louw, J.; Nkambule, B.B. A Systematic Review on the Protective Effect of N-Acetyl Cysteine Against Diabetes-Associated Cardiovascular Complications. Am. J. Cardiovasc. Drugs 2018, 18, 283–298.
  24. Pereira, J.E.G.; El Dib, R.; Braz, L.G.; Escudero, J.; Hayes, J.; Johnston, B.C. N-acetylcysteine use among patients undergoing cardiac surgery: A systematic review and meta-analysis of randomized trials. PLoS ONE 2019, 14, e0213862.
  25. Soleimani, A.; Habibi, M.R.; Hasanzadeh Kiabi, F.; Alipour, A.; Habibi, V.; Azizi, S.; Emami Zeydi, A.; Sohrabi, F.B. The effect of intravenous N-acetylcysteine on prevention of atrial fibrillation after coronary artery bypass graft surgery: A double-blind, randomised, placebo-controlled trial. Kardiol. Pol. 2018, 76, 99–106.
  26. Ozaydin, M.; Peker, O.; Erdogan, D.; Akcay, S.; Yucel, H.; Icli, A.; Ceyhan, B.M.; Sutcu, R.; Uysal, B.A.; Varol, E.; et al. Oxidative status, inflammation, and postoperative atrial fibrillation with metoprolol vs. carvedilol or carvedilol plus N-acetyl cysteine treatment. Clin. Cardiol. 2014, 37, 300–306.
  27. Ozaydin, M.; Icli, A.; Yucel, H.; Akcay, S.; Peker, O.; Erdogan, D.; Varol, E.; Dogan, A.; Okutan, H. Metoprolol vs. carvedilol or carvedilol plus N-acetyl cysteine on post-operative atrial fibrillation: A randomized, double-blind, placebo-controlled study. Eur. Heart J. 2013, 34, 597–604.
  28. Ozaydin, M.; Erdogan, D.; Yucel, H.; Peker, O.; Icli, A.; Akcay, S.; Etli, M.; Ceyhan, B.M.; Sutcu, R.; Varol, E.; et al. N-acetyl cysteine for the conversion of atrial fibrillation into sinus rhythm after cardiac surgery: A prospective, randomized, double-blind, placebo-controlled pilot study. Int. J. Cardiol. 2013, 165, 580–583.
  29. Ozaydin, M.; Peker, O.; Erdogan, D.; Kapan, S.; Turker, Y.; Varol, E.; Ozguner, F.; Dogan, A.; Ibrisim, E. N-acetylcysteine for the prevention of postoperative atrial fibrillation: A prospective, randomized, placebo-controlled pilot study. Eur. Heart J. 2008, 29, 625–631.
  30. Kazemi, B.; Akbarzadeh, F.; Safaei, N.; Yaghoubi, A.; Shadvar, K.; Ghasemi, K. Prophylactic high-dose oral-N-acetylcysteine does not prevent atrial fibrillation after heart surgery: A prospective double blind placebo-controlled randomized clinical trial. Pacing Clin. Electrophysiol. PACE 2013, 36, 1211–1219.
  31. Mehra, A.; Shotan, A.; Ostrzega, E.; Hsueh, W.; Vasquez-Johnson, J.; Elkayam, U. Potentiation of isosorbide dinitrate effects with N-acetylcysteine in patients with chronic heart failure. Circulation 1994, 89, 2595–2600.
  32. Dresdale, A.R.; Barr, L.H.; Bonow, R.O.; Mathisen, D.J.; Myers, C.E.; Schwartz, D.E.; d’Angelo, T.; Rosenberg, S.A. Prospective randomized study of the role of N-acetyl cysteine in reversing doxorubicin-induced cardiomyopathy. Am. J. Clin. Oncol. 1982, 5, 657–663.
  33. Unverferth, D.V.; Jagadeesh, J.M.; Unverferth, B.J.; Magorien, R.D.; Leier, C.V.; Balcerzak, S.P. Attempt to prevent doxorubicin-induced acute human myocardial morphologic damage with acetylcysteine. J. Natl. Cancer Inst. 1983, 71, 917–920.
  34. Roseguini, B.T.; Silva, L.M.; Polotow, T.G.; Barros, M.P.; Souccar, C.; Han, S.W. Effects of N-acetylcysteine on skeletal muscle structure and function in a mouse model of peripheral arterial insufficiency. J. Vasc. Surg. 2015, 61, 777–786.
  35. Lejay, A.; Charles, A.L.; Georg, I.; Goupilleau, F.; Delay, C.; Talha, S.; Thaveau, F.; Chakfe, N.; Geny, B. Critical Limb Ischaemia Exacerbates Mitochondrial Dysfunction in ApoE-/- Mice Compared with ApoE+/+ Mice, but N-acetyl Cysteine still Confers Protection. Eur. J. Vasc. Endovasc. Surg. 2019, 58, 576–582.
  36. Cui, Y.; Liu, L.; Xiao, Y.; Li, X.; Zhang, J.; Xie, X.; Tian, J.; Sen, C.K.; He, X.; Hao, H.; et al. N-acetylcysteine differentially regulates the populations of bone marrow and circulating endothelial progenitor cells in mice with limb ischemia. Eur. J. Pharmacol. 2020, 881, 173233.
  37. Zhu, Q.; Hao, H.; Xu, H.; Fichman, Y.; Cui, Y.; Yang, C.; Wang, M.; Mittler, R.; Hill, M.A.; Cowan, P.J.; et al. Combination of Antioxidant Enzyme Overexpression and N-Acetylcysteine Treatment Enhances the Survival of Bone Marrow Mesenchymal Stromal Cells in Ischemic Limb in Mice With Type 2 Diabetes. J. Am. Heart Assoc. 2021, 10, e023491.
  38. Fujii, H.; Li, S.H.; Szmitko, P.E.; Fedak, P.W.; Verma, S. C-reactive protein alters antioxidant defenses and promotes apoptosis in endothelial progenitor cells. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 2476–2482.
  39. Cui, Y.; Narasimhulu, C.A.; Liu, L.; Li, X.; Xiao, Y.; Zhang, J.; Xie, X.; Hao, H.; Liu, J.Z.; He, G.; et al. Oxidized low-density lipoprotein alters endothelial progenitor cell populations. Front. Biosci. 2015, 20, 975–988.
  40. Xu, Y.; Bu, H.; Jiang, Y.; Zhuo, X.; Hu, K.; Si, Z.; Chen, Y.; Liu, Q.; Gong, X.; Sun, H.; et al. N-acetyl cysteine prevents ambient fine particulate matter-potentiated atherosclerosis via inhibition of reactive oxygen species-induced oxidized low density lipoprotein elevation and decreased circulating endothelial progenitor cell. Mol. Med. Rep. 2022, 26, 236.
  41. Mann, D.L. Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circ. Res. 2002, 91, 988–998.
  42. Anker, S.D.; Coats, A.J. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int. J. Cardiol. 2002, 86, 123–130.
  43. Cailleret, M.; Amadou, A.; Andrieu-Abadie, N.; Nawrocki, A.; Adamy, C.; Ait-Mamar, B.; Rocaries, F.; Best-Belpomme, M.; Levade, T.; Pavoine, C.; et al. N-acetylcysteine prevents the deleterious effect of tumor necrosis factor-(alpha) on calcium transients and contraction in adult rat cardiomyocytes. Circulation 2004, 109, 406–411.
  44. Zhang, D.X.; Gutterman, D.D. Mitochondrial reactive oxygen species-mediated signaling in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 2007, 292, H2023–H2031.
  45. Forstermann, U.; Xia, N.; Li, H. Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis. Circ. Res. 2017, 120, 713–735.
  46. Rajagopalan, S.; Meng, X.P.; Ramasamy, S.; Harrison, D.G.; Galis, Z.S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J. Clin. Investig. 1996, 98, 2572–2579.
  47. Galis, Z.S.; Asanuma, K.; Godin, D.; Meng, X. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: New target for antioxidant therapy? Circulation 1998, 97, 2445–2453.
  48. Meng, X.P.; Yin, C.S.; Cui, J.H.; Li, Z.X.; Wang, L.; Wang, Y.W.; Li, Y.L. Inhibitory effect of N-acetylcysteine upon atherosclerotic processes in rabbit carotid. Zhonghua Yi Xue Za Zhi 2009, 89, 1850–1853.
  49. Sung, H.J.; Kim, J.; Kim, Y.; Jang, S.W.; Ko, J. N-acetyl cysteine suppresses the foam cell formation that is induced by oxidized low density lipoprotein via regulation of gene expression. Mol. Biol. Rep. 2012, 39, 3001–3007.
  50. Ivanovski, O.; Szumilak, D.; Nguyen-Khoa, T.; Ruellan, N.; Phan, O.; Lacour, B.; Descamps-Latscha, B.; Drueke, T.B.; Massy, Z.A. The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout mice. Kidney Int. 2005, 67, 2288–2294.
  51. Shimada, K.; Murayama, T.; Yokode, M.; Kita, T.; Uzui, H.; Ueda, T.; Lee, J.D.; Kishimoto, C. N-acetylcysteine reduces the severity of atherosclerosis in apolipoprotein E-deficient mice by reducing superoxide production. Circ. J. 2009, 73, 1337–1341.
  52. Fang, X.; Liu, L.; Zhou, S.; Zhu, M.; Wang, B. Nacetylcysteine inhibits atherosclerosis by correcting glutathionedependent methylglyoxal elimination and dicarbonyl/oxidative stress in the aorta of diabetic mice. Mol. Med. Rep. 2021, 23, 201.
  53. Lu, T.; Parthasarathy, S.; Hao, H.; Luo, M.; Ahmed, S.; Zhu, J.; Luo, S.; Kuppusamy, P.; Sen, C.K.; Verfaillie, C.M.; et al. Reactive oxygen species mediate oxidized low-density lipoprotein-induced inhibition of oct-4 expression and endothelial differentiation of bone marrow stem cells. Antioxid. Redox Signal. 2010, 13, 1845–1856.
  54. Zhang, Q.; Chen, L.; Si, Z.; Bu, H.; Narasimhulu, C.A.; Song, X.; Cui, M.Y.; Liu, H.; Lu, T.; He, G.; et al. Probucol Protects Endothelial Progenitor Cells Against Oxidized Low-Density Lipoprotein via Suppression of Reactive Oxygen Species Formation In Vivo. Cell. Physiol. Biochem. 2016, 39, 89–101.
  55. Rattan, A.K.; Arad, Y. Temporal and kinetic determinants of the inhibition of LDL oxidation by N-acetylcysteine (NAC). Atherosclerosis 1998, 138, 319–327.
  56. Cui, Y.; Narasimhulu, C.A.; Liu, L.; Zhang, Q.; Liu, P.Z.; Li, X.; Xiao, Y.; Zhang, J.; Hao, H.; Xie, X.; et al. N-acetylcysteine inhibits in vivo oxidation of native low-density lipoprotein. Sci. Rep. 2015, 5, 16339.
  57. Wolf, D.; Ley, K. Immunity and Inflammation in Atherosclerosis. Circ. Res. 2019, 124, 315–327.
  58. Libby, P.; Galis, Z.S. Cytokines regulate genes involved in atherogenesis. Ann. N. Y. Acad. Sci. 1995, 748, 158–168; discussion 168–170.
  59. Lee, Y.W.; Kuhn, H.; Hennig, B.; Neish, A.S.; Toborek, M. IL-4-induced oxidative stress upregulates VCAM-1 gene expression in human endothelial cells. J. Mol. Cell. Cardiol. 2001, 33, 83–94.
  60. Jain, S.K.; Kannan, K.; Lim, G.; Matthews-Greer, J.; McVie, R.; Bocchini, J.A., Jr. Elevated blood interleukin-6 levels in hyperketonemic type 1 diabetic patients and secretion by acetoacetate-treated cultured U937 monocytes. Diabetes Care 2003, 26, 2139–2143.
  61. Matsumoto, T.; Kobayashi, T.; Kamata, K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr. Med. Chem. 2007, 14, 3209–3220.
  62. Sonoki, K.; Iwase, M.; Ohdo, S.; Ieiri, I.; Matsuyama, N.; Takata, Y.; Kitazono, T. Telmisartan and N-acetylcysteine suppress group V secretory phospholipase A2 expression in TNFalpha-stimulated human endothelial cells and reduce associated atherogenicity. J. Cardiovasc. Pharmacol. 2012, 60, 367–374.
  63. Hayashi, K.; Takahata, H.; Kitagawa, N.; Kitange, G.; Kaminogo, M.; Shibata, S. N-acetylcysteine inhibited nuclear factor-kappaB expression and the intimal hyperplasia in rat carotid arterial injury. Neurol. Res. 2001, 23, 731–738.
  64. Spartalis, M.; Siasos, G.; Mastrogeorgiou, M.; Spartalis, E.; Kaminiotis, V.V.; Mylonas, K.S.; Kapelouzou, A.; Kontogiannis, C.; Doulamis, I.P.; Toutouzas, K.; et al. The effect of per os colchicine administration in combination with fenofibrate and N-acetylcysteine on triglyceride levels and the development of atherosclerotic lesions in cholesterol-fed rabbits. Eur. Rev. Med. Pharmacol. Sci. 2021, 25, 7765–7776.
  65. Arango Duque, G.; Descoteaux, A. Macrophage cytokines: Involvement in immunity and infectious diseases. Front. Immunol. 2014, 5, 491.
  66. Yuan, X.M.; Ward, L.J.; Forssell, C.; Siraj, N.; Li, W. Carotid Atheroma From Men Has Significantly Higher Levels of Inflammation and Iron Metabolism Enabled by Macrophages. Stroke 2018, 49, 419–425.
  67. Park, K.; Li, Q.; Evcimen, N.D.; Rask-Madsen, C.; Maeda, Y.; Maddaloni, E.; Yokomizo, H.; Shinjo, T.; St-Louis, R.; Fu, J.; et al. Exogenous Insulin Infusion Can Decrease Atherosclerosis in Diabetic Rodents by Improving Lipids, Inflammation, and Endothelial Function. Arterioscler. Thromb. Vasc. Biol. 2018, 38, 92–101.
  68. Cole, S.L.; Dunning, J.; Kok, W.L.; Benam, K.H.; Benlahrech, A.; Repapi, E.; Martinez, F.O.; Drumright, L.; Powell, T.J.; Bennett, M.; et al. M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza. JCI Insight. 2017, 2, e91868.
  69. Cochain, C.; Zernecke, A. Macrophages in vascular inflammation and atherosclerosis. Pflug. Arch. 2017, 469, 485–499.
  70. Zhu, Q.; Xiao, Y.; Jiang, M.; Liu, X.; Cui, Y.; Hao, H.; Flaker, G.C.; Liu, Q.; Zhou, S.; Liu, Z. N-acetylcysteine attenuates atherosclerosis progression in aging LDL receptor deficient mice with preserved M2 macrophages and increased CD146. Atherosclerosis 2022, 357, 41–50.
  71. Weber, C.; Noels, H. Atherosclerosis: Current pathogenesis and therapeutic options. Nat. Med. 2011, 17, 1410–1422.
  72. Pasupathy, S.; Tavella, R.; Grover, S.; Raman, B.; Procter, N.E.K.; Du, Y.T.; Mahadavan, G.; Stafford, I.; Heresztyn, T.; Holmes, A.; et al. Early Use of N-acetylcysteine With Nitrate Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction Reduces Myocardial Infarct Size (the NACIAM Trial ). Circulation 2017, 136, 894–903.
  73. Arstall, M.A.; Yang, J.; Stafford, I.; Betts, W.H.; Horowitz, J.D. N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects. Circulation 1995, 92, 2855–2862.
  74. Yesilbursa, D.; Serdar, A.; Senturk, T.; Serdar, Z.; Sag, S.; Cordan, J. Effect of N-acetylcysteine on oxidative stress and ventricular function in patients with myocardial infarction. Heart Vessel. 2006, 21, 33–37.
  75. Koramaz, I.; Pulathan, Z.; Usta, S.; Karahan, S.C.; Alver, A.; Yaris, E.; Kalyoncu, N.I.; Ozcan, F. Cardioprotective effect of cold-blood cardioplegia enriched with N-acetylcysteine during coronary artery bypass grafting. Ann. Thorac. Surg. 2006, 81, 613–618.
  76. Vento, A.E.; Nemlander, A.; Aittomaki, J.; Salo, J.; Karhunen, J.; Ramo, O.J. N-acetylcysteine as an additive to crystalloid cardioplegia increased oxidative stress capacity in CABG patients. Scand. Cardiovasc. J. SCJ 2003, 37, 349–355.
  77. Horowitz, J.D.; Henry, C.A.; Syrjanen, M.L.; Louis, W.J.; Fish, R.D.; Smith, T.W.; Antman, E.M. Combined use of nitroglycerin and N-acetylcysteine in the management of unstable angina pectoris. Circulation 1988, 77, 787–794.
  78. Marchetti, G.; Lodola, E.; Licciardello, L.; Colombo, A. Use of N-acetylcysteine in the management of coronary artery diseases. Cardiologia 1999, 44, 633–637.
  79. Talasaz, A.H.; Khalili, H.; Fahimi, F.; Mojtaba, S. Potential role of N-acetylcysteine in cardiovascular disorders. Therapy 2011, 8, 237–245.
  80. Gu, W.J.; Wu, Z.J.; Wang, P.F.; Aung, L.H.; Yin, R.X. N-Acetylcysteine supplementation for the prevention of atrial fibrillation after cardiac surgery: A meta-analysis of eight randomized controlled trials. BMC Cardiovasc. Disord. 2012, 12, 10.
  81. Lehnen, T.E.; Santos, M.V.; Lima, A.; Maia, A.L.; Wajner, S.M. N-Acetylcysteine Prevents Low T3 Syndrome and Attenuates Cardiac Dysfunction in a Male Rat Model of Myocardial Infarction. Endocrinology 2017, 158, 1502–1510.
  82. Senturk, T.; Cavun, S.; Avci, B.; Yermezler, A.; Serdar, Z.; Savci, V. Effective inhibition of cardiomyocyte apoptosis through the combination of trimetazidine and N-acetylcysteine in a rat model of myocardial ischemia and reperfusion injury. Atherosclerosis 2014, 237, 760–766.
  83. Meyer, M.; Bell, S.P.; Chen, Z.; Nyotowidjojo, I.; Lachapelle, R.R.; Christian, T.F.; Gibson, P.C.; Keating, F.F.; Dauerman, H.L.; LeWinter, M.M. High dose intracoronary N-acetylcysteine in a porcine model of ST-elevation myocardial infarction. J. Thromb. Thrombolysis 2013, 36, 433–441.
  84. Lu, H.; Daugherty, A. Atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2015, 35, 485–491.
  85. Calzadilla, P.; Gomez-Serrano, M.; Garcia-Santos, E.; Schiappacasse, A.; Abalde, Y.; Calvo, J.C.; Peral, B.; Guerra, L.N. N-Acetylcysteine affects obesity-related protein expression in 3T3-L1 adipocytes. Redox Rep. 2013, 18, 210–218.
  86. Pieralisi, A.; Martini, C.; Soto, D.; Vila, M.C.; Calvo, J.C.; Guerra, L.N. N-acetylcysteine inhibits lipid accumulation in mouse embryonic adipocytes. Redox Biol. 2016, 9, 39–44.
  87. Scanu, A.M.; Fless, G.M. Lipoprotein(a). Heterogeneity and biological relevance. J. Clin. Investig. 1990, 85, 1709–1715.
  88. Kroon, A.A.; Demacker, P.N.; Stalenhoef, A.F. N-acetylcysteine and serum concentrations of lipoprotein(a). J. Intern. Med. 1991, 230, 519–526.
  89. Wiklund, O.; Fager, G.; Andersson, A.; Lundstam, U.; Masson, P.; Hultberg, B. N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels. Atherosclerosis 1996, 119, 99–106.
  90. McCully, K.S. Homocysteine and the pathogenesis of atherosclerosis. Expert Rev. Clin. Pharmacol. 2015, 8, 211–219.
  91. Bostom, A.G.; Shemin, D.; Yoburn, D.; Fisher, D.H.; Nadeau, M.R.; Selhub, J. Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients. Atherosclerosis 1996, 120, 241–244.
  92. Ventura, P.; Panini, R.; Pasini, M.C.; Scarpetta, G.; Salvioli, G. N -Acetyl-cysteine reduces homocysteine plasma levels after single intravenous administration by increasing thiols urinary excretion. Pharmacol. Res. 1999, 40, 345–350.
  93. Hildebrandt, W.; Sauer, R.; Bonaterra, G.; Dugi, K.A.; Edler, L.; Kinscherf, R. Oral N-acetylcysteine reduces plasma homocysteine concentrations regardless of lipid or smoking status. Am. J. Clin. Nutr. 2015, 102, 1014–1024.
  94. Miner, S.E.; Cole, D.E.; Evrovski, J.; Forrest, Q.; Hutchison, S.J.; Holmes, K.; Ross, H.J. N-acetylcysteine neither lowers plasma homocysteine concentrations nor improves brachial artery endothelial function in cardiac transplant recipients. Can. J. Cardiol. 2002, 18, 503–507.
  95. Xu, S.; Ilyas, I.; Little, P.J.; Li, H.; Kamato, D.; Zheng, X.; Luo, S.; Li, Z.; Liu, P.; Han, J.; et al. Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Pharmacol. Rev. 2021, 73, 924–967.
  96. Toborek, M.; Barger, S.W.; Mattson, M.P.; McClain, C.J.; Hennig, B. Role of glutathione redox cycle in TNF-alpha-mediated endothelial cell dysfunction. Atherosclerosis 1995, 117, 179–188.
  97. Yang, W.S.; Lee, J.M.; Han, N.J.; Kim, Y.J.; Chang, J.W.; Park, S.K. Mycophenolic acid attenuates tumor necrosis factor-alpha-induced endothelin-1 production in human aortic endothelial cells. Atherosclerosis 2010, 211, 48–54.
  98. Voghel, G.; Thorin-Trescases, N.; Farhat, N.; Mamarbachi, A.M.; Villeneuve, L.; Fortier, A.; Perrault, L.P.; Carrier, M.; Thorin, E. Chronic treatment with N-acetyl-cystein delays cellular senescence in endothelial cells isolated from a subgroup of atherosclerotic patients. Mech. Ageing Dev. 2008, 129, 261–270.
  99. Creager, M.A.; Roddy, M.A.; Boles, K.; Stamler, J.S. N-acetylcysteine does not influence the activity of endothelium-derived relaxing factor in vivo. Hypertension 1997, 29, 668–672.
  100. Andrews, N.P.; Prasad, A.; Quyyumi, A.A. N-acetylcysteine improves coronary and peripheral vascular function. J. Am. Coll. Cardiol. 2001, 37, 117–123.
  101. Pedre, B.; Barayeu, U.; Ezerina, D.; Dick, T.P. The mechanism of action of N-acetylcysteine (NAC): The emerging role of H(2)S and sulfane sulfur species. Pharmacol. Ther. 2021, 228, 107916.
  102. Tieu, S.; Charchoglyan, A.; Paulsen, L.; Wagter-Lesperance, L.C.; Shandilya, U.K.; Bridle, B.W.; Mallard, B.A.; Karrow, N.A. N-Acetylcysteine and Its Immunomodulatory Properties in Humans and Domesticated Animals. Antioxidants 2023, 12, 1867.
  103. Sakai, M.; Yu, Z.; Taniguchi, M.; Picotin, R.; Oyama, N.; Stellwagen, D.; Ono, C.; Kikuchi, Y.; Matsui, K.; Nakanishi, M.; et al. N-Acetylcysteine Suppresses Microglial Inflammation and Induces Mortality Dose-Dependently via Tumor Necrosis Factor-alpha Signaling. Int. J. Mol. Sci. 2023, 24, 3798.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Academic Video Service
Feedback